Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of ONO-4538 in Japanese Participants with Sepsis or Septic Shock

Trial Profile

Phase 1/2 Study of ONO-4538 in Japanese Participants with Sepsis or Septic Shock

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Sepsis; Septic shock
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 01 Oct 2018 Status changed from active, no longer recruiting to completed.
    • 08 May 2018 Status changed from recruiting to active, no longer recruiting.
    • 13 Nov 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top